Hunter Associates Investment Management LLC Has $11.40 Million Holdings in ResMed Inc. (NYSE:RMD)

Hunter Associates Investment Management LLC decreased its stake in shares of ResMed Inc. (NYSE:RMD) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,835 shares of the medical equipment provider’s stock after selling 530 shares during the quarter. ResMed comprises approximately 1.7% of Hunter Associates Investment Management LLC’s investment portfolio, making the stock its 13th largest holding. Hunter Associates Investment Management LLC’s holdings in ResMed were worth $11,395,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of RMD. True Wealth Design LLC grew its holdings in ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of ResMed in the 3rd quarter valued at about $34,000. Rosenberg Matthew Hamilton bought a new stake in ResMed in the 4th quarter valued at about $54,000. Capital Performance Advisors LLP bought a new stake in ResMed in the 3rd quarter valued at about $60,000. Finally, Quarry LP raised its stake in ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 242 shares during the period. Institutional investors own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on RMD. KeyCorp raised their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, October 25th. The Goldman Sachs Group started coverage on shares of ResMed in a report on Thursday, January 16th. They set a “buy” rating for the company. Finally, Stifel Nicolaus started coverage on shares of ResMed in a report on Friday, December 13th. They issued a “hold” rating and a $250.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ResMed has a consensus rating of “Moderate Buy” and an average price target of $238.40.

Insider Buying and Selling at ResMed

In other news, insider Justin Leong sold 6,160 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the sale, the insider now owns 21,718 shares of the company’s stock, valued at $5,279,428.62. The trade was a 22.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,030 shares of company stock worth $2,702,687 over the last three months. 0.71% of the stock is currently owned by insiders.

ResMed Stock Performance

Shares of RMD opened at $257.63 on Friday. The stock has a 50 day moving average of $240.04 and a 200 day moving average of $235.84. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $170.56 and a 12 month high of $263.05. The company has a market capitalization of $37.82 billion, a price-to-earnings ratio of 34.12, a PEG ratio of 1.83 and a beta of 0.70.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 25.53% and a net margin of 23.15%. As a group, sell-side analysts forecast that ResMed Inc. will post 9.35 earnings per share for the current year.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.